MicroRNA gene polymorphisms and the risk of colorectal cancer

GUO-QIANG RONG[1,3*], XIN-MEI ZHANG[2*], BO CHEN[1*], XIAO-DONG YANG[1],
HAO-RONG WU[1] and WEI GONG[3]

[1]Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004;
[2]Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006;
[3]Department of Surgery, The Fifth People's Hospital of Changshu, Changshu, Jiangsu 215500, P.R. China

Abstract. The present study was carried out to demonstrate the epidemiological value of microRNA (miRNA) in colorectal cancer (CRC) by investigating the association between miRNA gene polymorphisms and the susceptibility to CRC. Multiple meta-analyses of reported data were conducted, and odds ratio values and 95% confidence intervals were used to assess these associations. Stata 11.0 software was used to analyze the data and the modified Jadad quality score was employed to evaluate the quality of the retrieved studies. We retrieved 38 studies on the association between miRNA polymorphisms and risk of CRC, however only 15 met the requirements of the inclusion criteria. In conclusion, we identified a variety of miRNAs (miRNA-let-7, miR-34b/c, miR-146a, miR-603 and miR-149) gene polymorphisms that are associated with susceptibility to CRC. However, some miRNAs (miR-192a, miR-608 and miR-27a) are associated with CRC, but not susceptibility to CRC. The results have limitations given the relatively low number of studies available. Therefore, it is necessary to collect data from large sample-size studies to further validate the results.

Introduction

Colorectal cancer (CRC) is a common malignant tumor that occurs worldwide. According to statistics, both the incidence and mortality of CRC rank third among all forms of cancer in the United States, even though the mortality rates have declined. The vast majority of cases (90%) occur in individuals over 50 years of age (1). Apart from hereditary CRC, the development of this cancer type is poorly understood (2,3). Both germline and somatic genetic variations have been suggested as contributing factors in CRC development (4-6).

MicroRNA (miRNA) refers to a group of small non-coding RNAs that are ~22 (18-25) nucleotides in length and which regulate RNA expression at the translational level (7-9). miRNAs have been associated with a variety of diseases, including different forms of cancer. Increasing evidence has confirmed the importance of miRNAs in regulating common biological characteristics/processes of different tumors, such as: self-growth signals, insensitivity to anti-growth signals, abnormal apoptosis, unlimited replication potential, sustained induction of angiogenesis, invasion, and metastasis (10). Many researchers have identified tumor-specific miRNA signatures which accurately distinguish malignant tumors from several different parts of the benign tissue, and their results showed that some miRNAs are carcinogenic depending on other genetic mutations present in tumors (11). miRNA species can directly affect cell proliferation and apoptosis of tumor cell lines. Furthermore, many studies have confirmed the link between abnormal miRNA expression and abnormalities in intracellular signal transduction pathways and tumorigenesis (12-16). For example, miR-9 is activated by YC/MYCN, which induces cancer metastasis by regulating the expression of metastasis suppressor protein, E-cadherin (17), and miR-449a can cause retinoblastoma (Rb)-dependent cell cycle arrest and cellular senescence of prostate cancer (18).

miRNAs constitute a new class of molecules that through interaction with oncogenes and/or tumor suppressor genes, can promote the formation of cancer (19). However, different miRNAs regulate different signaling pathways and different target proteins/genes that affect the biological changes characteristic of cancer.

Previous findings showed that human miRNAs with single-nucleotide polymorphisms (SNPs) can be targets of genetic variation in human genomic DNA sequences and may be related to susceptibility of human disease (20). miRNA SNPs have inter-individual differences in disease diagnosis, treatment, and prognosis. Recent large-scale studies reported significant risks associated with different germline variations for development of CRC (5). In addition, novel studies suggest

Correspondence to: Dr Xiao-Dong Yang or Dr Hao-Rong Wu, Department of General Surgery, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, Jiangsu 215004, P.R. China
E-mail: wjyxd@163.com
E-mail: yaqi020622@sina.com

*Contributed equally

Table I. Characteristics of the 15 studies included in the meta-analysis.

miRNA	SNP ID	Author (Refs.)	Year	Ethnicity	Study design	Genotyping method	Allele	Case no.	Control no.	HWE (P-value)	Jadad
miRNA-146a	rs2910164	Min *et al* (24)	2012	Asian	PB	PCR-RFLP	C/G	446	502	0.44	7
		Hezova *et al* (25)	2012	Caucasian	HB	TaqMan	C/G	197	212	0.41	7
		Ma *et al* (26)	2013	Asian	HB	TaqMan	C/G	1,147	1,203	0.075	7
		Lv *et al* (27)	2013	Asian	HB	PCR-RFLP	C/G	353	540	0.08	7
		Vinci *et al* (28)	2013	Caucasian	PB	HRM	C/G	160	178	0.11	6
		Hu *et al* (29)	2014	Asian	HB	PCR-RFLP	C/G	276	373	0.14	7
		Parlayan *et al* (30)	2014	Asian	HB	TaqMan	C/G	116	524	0.75	7
miRNA-149	rs2292832	Min *et al* (24)	2012	Asian	PB	PCR-RFLP	C/T	446	502	0.17	7
		Lv *et al* (27)	2013	Asian	HB	PCR-RFLP	C/T	353	540	<0.05	7
		Vinci *et al* (28)	2013	Caucasian	PB	HRM	C/T	160	178	0.91	6
miRNA-196a2	rs11614913	Min *et al* (24)	2012	Asian	PB	PCR-RFLP	T/C	446	502	0.63	7
		Hezova *et al* (25)	2012	Caucasian	HB	TaqMan	T/C	197	212	0.81	7
		Lv *et al* (27)	2013	Asian	PB	PCR-RFLP	T/C	353	540	<0.05	7
		Vinci *et al* (28)	2013	Caucasian	PB	HRM	T/C	160	178	0.09	6
		Parlayan *et al* (30)	2014	Asian	HB	TaqMan	T/C	116	524	0.78	7
		Zhu *et al* (31)	2012	Asian	HB	TaqMan	T/C	573	588	0.17	7
		Zhan *et al* (32)	2011	Asian	HB	PCR-RFLP	T/C	252	543	0.77	7
		Chen *et al* (33)	2012	Asian	HB	PCR-LDR	T/C	126	407	0.82	7
miRNA-27a	rs895819	Hezova *et al* (25)	2012	Caucasian	HB	TaqMan	G/A	197	212	0.78	7
		Wang *et al* (34)	2014	Asian	HB	TaqMan	G/A	205	455	<0.05	7
miRNA-34b/c	rs4938723	Gao *et al* (35)	2013	Asian	HB	PCR-RFLP	T/C	347	488	0.83	7
		Oh *et al* (36)	2014	Asian	PB	PCR-RFLP	T/C	545	428	0.4	7
miRNA-let-7	rs712	Pan *et al* (37)	2014	Asian	HB	PCR-RFLP	G/T	339	313	0.41	7
miRNA-603	rs11014002	Wang *et al* (38)	2014	Asian	HB	Sequenom mass	C/T	102	204	0.59	7
miRNA-608	rs4919510	Ryan *et al* (39)	2012	Caucasian	PB	TaqMan	C/G	245	446	0.94	7

PB, population-based case-control studies; HB, hospital-based case-control studies; PCR-RFLP, polymerase chain reaction with restriction fragment length polymorphism; HRM, high resolution melt; SNP, single nucleotide polymorphisms; HWE, Hardy-Weinberg equilibrium; Jadad, modified Jadad score.

a potential influence of miRNA SNPs on the risk of cancer development.

Therefore, the aim of the present study was to investigate the correlation between miRNA gene polymorphisms and the susceptibility to CRC by reviewing the literature.

Materials and methods

Screening and identification of relevant studies. We identified eligible and relevant studies by performing searches with the terms 'miRNA/microRNA', 'colorectal cancer', 'genotype', 'polymorphism', and 'variant' in the PubMed, Ovid, and Embase databases, as well as the Cochrane Library. The search was limited to English language studies and only published studies with full text were included. We evaluated potentially relevant publications by manually examining their titles and abstracts. The selected studies in our meta-analysis also matched the following inclusion criteria: i) Assessment of miRNA polymorphisms and the risks of suffering from CRC; ii) an individual case-control study in humans; iii) statistically sufficient genotype data by

odds ratio (OR) values and 95% confidence intervals (CI); and iv) full-text search. Exclusion criteria were: i) Lack of controlled studies; ii) repeat of previous literature; iii) summaries, comments, reviews and editorials; and iv) focus on benign CRC tumors.

Data extraction and study characteristics. Two researchers independently extracted the data that met the above inclusion criteria and differences were resolved through discussion. For each study, the following information was extracted: Last name of first author, year of publication, ethnicity of patients in different studies, miRNA type, SNP ID, source of research, genotyping method, number of cases and controls, number of various genotypes among cases and controls, and the Hardy-Weinberg equilibrium of control subjects. If a study did not provide complete data, we sent a request to the corresponding author for the data. A total of 15 eligible studies met the inclusion criteria (Table I).

Quality assessment. Two researchers evaluated the uniform quality of studies which met the inclusion criteria, and

Figure 1. Flow chart of study selection.

cross-checked in case of disagreement, which was eventually resolved by discussion. The quality of the included studies was assessed using a modified Jadad score (21), where 1-3 points was considered a low quality study, and 4-7 points was considered high-quality research. Evaluation included whether to generate a random sequence by hiding the proper randomized allocation; whether the study was blinded, and whether the patients were lost or quit the study (Table I).

Statistical analysis. According to the genotype frequencies of cases and controls, the correlation between miRNA polymorphisms and risk of CRC was assessed via OR values with 95% CI. We performed statistical analyses of OR values and 95% CI by assessing five different genetic parameters: The allele, the dominant genetic model, the recessive genetic model, the homozygous comparison, and the heterozygous comparison. The Chi-square based Q statistic was used to assess heterogeneity between studies and P<0.05 was considered to indicate significant heterogeneity between studies. The I^2 index was expressed as a percentage for the total variability throughout the study. I^2 value of 25, 50 and 75% indicated low, medium, and high heterogeneity, respectively. Funnel plots were used to assess publication bias. When the effects were assumed to be homogeneous, the fixed-effects model was used (Mantel-Haenszel method). If heterogeneity was present, the random-effects model was applied (DerSimonian and Laird method) to account for inter-study heterogeneity instead of the fixed-effect model. Data were analyzed with Stata 11.0 software (StataCorp, College Station, USA) and all P-values were two-sided tests (22,23).

Results

Study characteristics. A total of 681 studies relevant to the search words were identified and only 38 studies were on the association between CRC and miRNA polymorphisms. According to the aforementioned inclusion and exclusion criteria, 16 publications (four using population-based controls and 11 using hospital-based controls) were included in the final meta-analysis (24-39) (Fig. 1). Of the 15 articles, seven related to miR-146a; three were on miRNA-149; eight were

on miRNA-196a2; there were two each related to miRNA-27a and miRNA-34b/c; and there was one each on miRNA-let-7, miRNA-603, and miRNA-608. The main characteristics of the studies included in the meta-analysis are summarized in Table I.

Overall analyses. Table II shows that the overall analysis of all the studies revealed a statistically significant positive association between miRNA-let-7, miR-34b/c, miR-146a, and miR-149 polymorphisms and the risk of CRC. However, miR-196a2 (31-33), miR-27 (34), miR-603 (38) and miR-608 (39) did not correlate with the risk of CRC. Only significantly different results follow.

Analysis of miR-146a polymorphisms and susceptibility to CRC. i) Seven studies (24-30) reported the association between G/C alleles and susceptibility to CRC, there was no significant heterogeneity between studies (I^2=26.4%, P=0.227), and the fixed-effect model was used. The total analysis showed that individuals with the G allele are more susceptible to CRC than with C (OR=1.09, 95% CI=1.01-1.18, P=0.02). ii) Seven studies (24-30) reported the association between the recessive genetic model, GG/(CC+GC), and susceptibility to CRC, there was no significant heterogeneity between studies (I^2=28.9%, P=0.207), and the fixed-effect model was used. The total analysis showed that people with the recessive genetic model, GG, are more susceptible to CRC than (CC+GC) (OR=1.13, 95% CI=1.00-1.28, P=0.047). iii) Seven studies (24-30) reported the association between homozygous GG/CC and the susceptibility to CRC, there was no significant heterogeneity between studies (I^2=25.2%, P=0.237), and the fixed-effect model was used. The total analysis showed that people with homozygous GG are more susceptible to CRC than CC (OR=1.19, 95% CI=1.01-1.41, P=0.042).

Analysis of miRNA-149 polymorphisms and susceptibility to CRC. Five studies (24-28) reported the association between the recessive genetic model, TT/(TC+CC), and susceptibility to CRC, there was no significant heterogeneity between studies (I^2=0, P=0.582), and the fixed-effect model was used. The total

Table II. Analysis of the association between 8 miRNA gene polymorphism and risk of CRC.

miRNA	Contrast	N[a]	P-value[b]	OR (95% CI)	I² (%)	P-value[c]	P-value[d]
miRNA-146a		7					
	G/C		0.02	1.09 (1.01-1.18)	26.4	0.227	0.036
	GC+GG/CC		0.068	1.13 (0.99-1.27)	75.1	0.001	0.527
	GG/CC+GC		0.047	1.13 (1.00-1.28)	28.9	0.207	0.155
	GG/CC		0.042	1.19 (1.01-1.41)	25.2	0.237	0.141
	GC/CC		0.191	1.09 (0.94-1.24)	79.8	<0.001	0.646
miRNA-149		3					
	T/C		0.082	1.13 (0.96-1.3)	0	0.533	0.805
	TT+CT/CC		0.871	1.02 (0.79-1.31)	0	0.655	0.06
	TT/TC+CC		0.025	1.24 (1.03-1.5)	0	0.582	0.332
	TT/CC		0.241	1.19 (0.89-1.6)	0	0.591	0.4
	TC/CC		0.382	0.88 (0.67-1.16)	0	0.89	0.191
miRNA-196a2		8					
	T/C		0.747	1.01 (0.94-1.1)	89.2	<0.001	0.595
	TT+TC/CC		0.656	1.03 (0.9-1.17)	87.6	<0.001	0.011
	TT/TC+CC		0.898	1.01 (0.89-1.15)	83	<0.001	0.636
	TT/CC		0.763	1.03 (0.87-1.21)	90.2	<0.001	0.061
	TC/CC		0.49	1.05 (0.91-1.2)	84.7	<0.001	0.023
miRNA-27a		2					
	G/A		0.057	1.19 (0.99-1.43)	66.4	0.085	-
	(GG+GA)/AA		0.221	1.14 (0.9-1.55)	48.1	0.165	-
	GG/(GA+AA)		0.082	1.3 (0.97-1.74)	3.3	0.309	-
	GG/AA		0.071	1.38 (0.97-1.95)	39	0.201	-
	GA/AA		0.569	1.09 (0.81-1.47)	0	0.408	-
miRNA-34b/c		2					
	T/C		0.058	1.15 (1-1.33)	50.9	0.154	-
	TT+TC/CC		0.016	1.49 (1.08-2.06)	0	0.519	-
	TT/(TC+CC)		0.288	1.11 (0.92-1.33)	50	0.157	-
	TT/CC		0.015	1.52 (1.08-2.13)	0	0.342	-
	TC/CC		0.032	1.46 (1.03-2.05)	0	0.812	-
miRNA-let-7		1					
	T/G		0.003	1.49 (1.15-1.94)	-	-	-
	TT+TG/GG		0.015	1.48 (1.08-2.03)	-	-	-
	TT/TG+GG		0.015	2.52 (1.19-5.31)	-	-	-
	TT/GG		0.007	2.81 (1.32-5.98)	-	-	-
	TG/GG		0.074	1.35 (0.97-1.88)	-	-	-
miRNA-603		1					
	C/T		0.154	0.74 (0.50-1.12)	-	-	-
	CC+CT/TT		0.517	1.05 (0.59-1.87)	-	-	-
	CC/CT+TT		0.152	0.94 (0.69-1.29)	-	-	-
	CC/TT		0.398	1.02 (0.56-1.85)	-	-	-
	CT/TT		0.778	1.10 (1.60-2.02)	-	-	-
miRNA-608		1					
	C/G		0.829	0.97 (0.76-1.25)	-	-	-
	CG+CC/GG		0.869	1.05 (0.59-1.87)	-	-	-
	CC/CG+GG		0.716	0.94 (0.69-1.29)	-	-	-
	CC/GG		0.956	1.02 (0.56-1.85)	-	-	-
	CG/GG		0.769	1.10 (0.59-2.02)	-	-	-

[a]Number of comparison. [b]P-value of test for overall effect. [c]P-value of heterogeneity. [d]Egger's test. miRNA, microRNA; CRC, colorectal cancer; OR, odds ratio; CI, confidence interval.

analysis showed that people with the recessive genetic model, TT, are more susceptible to CRC than (TC+CC) (OR=1.24, 95% CI=1.03-1.5, P=0.025).

Analysis of miRNA-34b/c polymorphisms and susceptibility to CRC. i) Two studies (35,36) reported the association between the dominant genetic model, TT+TC/CC, and susceptibility to CRC, there was no significant heterogeneity between studies ($I^2=0$, P=0.519), and the fixed-effect model was used. The total analysis showed that people with the dominant model, TT+TC, are more susceptible to CRC than CC (OR=1.49, 95% CI=1.08-2.06, P=0.016). ii) Two studies (34,35) reported the association between the homozygous model, TT/CC, and susceptibility to CRC, there was no significant heterogeneity between studies ($I^2=0$, P=0.342), and the fixed-effect model was used. The total analysis showed that people with the homozygous model, TT, are more susceptible to CRC than CC (OR=1.52, 95% CI=1.08-2.13, P=0.015). iii) Two studies (34,35) reported the association between the heterozygous model, TC/CC, and susceptibility to CRC, there was no significant heterogeneity between studies ($I^2=0$, P=0.812), and the fixed-effect model was used. The total analysis showed that people with the heterozygous model, TC, are more susceptible to CRC than CC (OR=1.46, 95% CI=1.03-2.05, P=0.032).

Analysis of miRNA-let-7 polymorphisms and susceptibility to CRC. i) One study (37) reported the association between the allele, T/G, and susceptibility to CRC. The analysis showed that people with allele T are more susceptible to CRC than G (OR=1.49, 95% CI=1.15-1.94, P=0.003). ii) One study (37) reported the association between the dominant genetic model, TT+TG/GG, and susceptibility to CRC. The analysis showed that people with the dominant genetic model, TT+TG, are more susceptible to CRC than GG (OR=1.48, 95% CI=1.08-2.03, P=0.015). iii) One study (37) reported the association between the recessive genetic model, TT/GG+TG, and susceptibility to CRC. The analysis showed that people with the recessive genetic model, TT, are more susceptible to CRC than GG+TG (OR=2.52, 95% CI=1.19-5.31, P=0.015). iv) One study (37) reported the association between the homozygous model, TT/GG, and susceptibility to CRC. The analysis showed that people with the homozygous model, TT, are more susceptible to CRC than GG (OR=2.81, 95% CI=1.32-5.98, P=0.007).

These results indicate that miRNA-let-7, miR-34b/c, miR-146a, and miR-149 polymorphisms were positively correlated with CRC.

Statistical sensitivity. Statistical sensitivity where one study was removed and the rest were analyzed, the pooled relative risks (RRs) were similar with the overall pooled RRs (data not shown), supporting the robustness of our results.

Publication bias. Egger's test was used to assess the publication bias of the studies (Table II). The results show some evidence of publication bias in some comparisons.

Discussion

At present, miRNA gene polymorphisms and susceptibility to a variety of tumors have been reported. De Ruyck *et al*

found that miRNA-let-7 polymorphisms in the KRAS 3'-UTR are a prognostic factor of oropharyngeal cancer (40). Another study showed that miR-146aG>C and miR-196a2C>T polymorphisms were associated with the risk of hepatocellular carcinoma (HCC) in patients in China, especially in patients with hepatitis B virus infection (41). Palmieri *et al* found that miR-146a polymorphisms are not associated with tumor development in oral squamous cell carcinoma. However, a slight increase in the frequency of the variant allele was observed in stage II tumors (42).

There are also several meta-analyses that statistically correlated with miRNAs and cancer risk. Some meta-analysis studies evaluated the correlation between one miRNA and a single cancer susceptibility. Wang *et al* confirmed the association of the polymorphism, miR-196a2 rs11614913, with the risk of CRC, but not with tumor stage and grade (43). Some meta-analysis studies evaluated the correlation between one miRNA and a variety of cancer susceptibilities. Tao *et al* suggested that the hsa-miR-34b/c rs4938723 polymorphism may play opposite roles in different types of cancer based on the present studies, and a subgroup analysis revealed that the variant CT genotypes were associated with an increased risk of HCC compared with the wild-type TT genotype. However, a decreased risk of CRC was found in the genetic model of CC/TT and CC/CT+TT (44). Li *et al* reported that the miR-146a rs2910164 polymorphism may decrease the susceptibility of digestive system cancers, especially in the Asian population (45). Some meta-analysis studies evaluated the correlation between a variety of miRNAs and a variety of cancer susceptibilities. For example, one meta-analysis provided evidence that the miR-196a2 rs11614913 polymorphism is associated with an increased cancer risk and rs2910164 in miR-146a may be associated with susceptibility to papillary thyroid carcinoma and cervical cancer (46). In addition, some studies analyzed the correlation between a variety of miRNAs and a specific cancer susceptibility. Dikeakos *et al* investigated the association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with the risk of gastric cancer and survival in the Greek population (47). They found that the risk of gastric cancer was significantly higher in carriers of miR-149 rs2292832CC and miR-196a2 rs11614913CC genotypes, as well as for carriers of the rs2910164/rs2292832/rs11614913 CCC and GTC haplotype. The rs2910164/rs2292832/rs11614913 CTT and CCT haplotypes appear to have a protective role against the development of gastric cancer. Their data demonstrate that specific miRNA SNPs are associated with gastric cancer susceptibility in the Greek population (47).

In the present study, we performed statistical analyses of the relationships between miRNA polymorphisms and CRC. We investigated the effects of miRNA-196a2, miRNA-146a, miRNA-27a, miRNA-34b/c, miRNA-let-7, miRNA-603, miRNA-608 and miRNA-149 on CRC susceptibility. This was a more comprehensive statistical analysis of the various miRNAs that affect the risk of CRC. However, regardless of whether the aforementioned miRNA and risk of CRC risk are highly relevant, they are combined with other factors such as *Helicobacter pylori* (48), smoking (49,50), age (49,50), and drugs, which can lead to increased cancer risk. Therefore, stratified analysis is necessary. In addition, the limitation of this study is that most enrolled studies involved Asian

poplations, and the results may not be generalized to the global population. Therefore, we need a larger number of samples for statistical analysis, and more data on the relationship between miRNA gene polymorphisms and CRC among non-Asian populations, to make more reliable conclusions.

In conclusion, we statistically analyzed the relationship between miRNA gene polymorphisms and CRC prevalence through a meta-analysis of several publications. miRNA-let-7, miR-34b/c, miR-146a, miR-603, and miR-149 gene polymorphisms can significantly increase the risk of CRC, while miR-192a and miR-27a polymorphisms are not related to the risk of CRC. Analyses of a larger number of samples are required.

Acknowledgements

References

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, Tjønneland A, Overvad K, Jensen MK, Boutron-Ruault MC, *et al*: Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 121: 2065-2072, 2007.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
4. Corté H, Manceau G, Blons H and Laurent-Puig P: MicroRNA and colorectal cancer. Dig Liver Dis 44: 195-200, 2012.
5. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bézieau S, Brenner H, Butterbach K, *et al*; Colon Cancer Family Registry and the Genetics and Epidemiology of Colorectal Cancer Consortium: Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 144: 799-807. e724, 2013.
6. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, *et al*: Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158, 2007.
7. Kusenda B, Mraz M, Mayer J and Pospisilova S: MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 205-215, 2006.
8. Place RF, Li LC, Pookot D, Noonan EJ and Dahiya R: MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105: 1608-1613, 2008.
9. Vasudevan S, Tong Y and Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931-1934, 2007.
10. Santarpia L, Nicoloso M and Calin GA: MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocr Relat Cancer 17: F51-F75, 2010.
11. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R and Haqq C: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24, 2006.
12. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, *et al*: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
13. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, *et al*: Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27: 3880-3888, 2008.
14. Lanza G, Ferracin M, Gafà R, Veronese A, Spizzo R, Pichiorri F, Liu CG, Calin GA, Croce CM and Negrini M: mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 6: 54, 2007.
15. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR and Israel MA: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67: 2456-2468, 2007.
16. Saito Y, Suzuki H and Hibi T: The role of microRNAs in gastro-intestinal cancers. J Gastroenterol 44 (Suppl 19): 18-22, 2009.
17. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, *et al*: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010.
18. Noonan EJ, Place RF, Basak S, Pookot D and Li LC: miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 1: 349-358, 2010.
19. Panarelli NC and Yantiss RK: Microrna expression in selected carcinomas of the gastrointestinal tract. Pathol Res Int 2011: 124608, 2011.
20. Wu D, Yang G, Zhang L, Xue J, Wen Z and Li M: Genome-wide association study combined with biological context can reveal more disease-related SNPs altering microRNA target seed sites. BMC Genomics 15: 669, 2014.
21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
22. Wang J, Bi J, Liu X, Li K, Di J and Wang B: Has-miR-146a polymorphism (rs2910164) and cancer risk: a meta-analysis of 19 case-control studies. Mol Biol Rep 39: 4571-4579, 2012.
23. Xu X, Yang X, Ru G, Wu Y, Zhang S, Xing C, Wu Y and Cao J: miR-146a gene polymorphism rs2910164 and the risk of digestive tumors: a meta-analysis of 21 case-control studies. Oncol Rep 31: 472-479, 2014.
24. Min KT, Kim JW, Jeon YJ, Jang MJ, Chong SY, Oh D and Kim NK: Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog 51 (Suppl 1): E65-E73, 2012.
25. Hezova R, Kovarikova A, Bienertova-Vasku J, Sachlova M, Redova M, Vasku A, Svoboda M, Radova L, Kiss I, Vyzula R, *et al*: Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol 18: 2827-2831, 2012.
26. Ma L, Zhu L, Gu D, Chu H, Tong N, Chen J, Zhang Z and Wang M: A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch Toxicol 87: 825-833, 2013.
27. Lv M, Dong W, Li L, Zhang L, Su X, Wang L, Gao L and Zhang L: Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population. J Cancer Res Clin Oncol 139: 1405-1410, 2013.
28. Vinci S, Gelmini S, Mancini I, Malentacchi F, Pazzagli M, Beltrami C, Pinzani P and Orlando C: Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods 59: 138-146, 2013.
29. Hu X, Li L, Shang M, Zhou J, Song X, Lu X, Wang J, Ying B and Wang L: Association between microRNA genetic variants and susceptibility to colorectal cancer in Chinese population. Tumour Biol 35: 2151-2156, 2014.
30. Parlayan C, Ikeda S, Sato N, Sawabe M, Muramatsu M and Arai T: Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study. Asian Pac J Cancer Prev 15: 2101-2107, 2014.
31. Zhu L, Chu H, Gu D, Ma L, Shi D, Zhong D, Tong N, Zhang Z and Wang M: A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol 31: 350-354, 2012.
32. Zhan JF, Chen LH, Chen ZX, Yuan YW, Xie GZ, Sun AM and Liu Y: A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res 42: 144-148, 2011.

33. Chen H, Sun LY, Chen LL, Zheng HQ and Zhang QF: A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Intern Med J 42: e115-e119, 2012.
34. Wang Z, Sun X, Wang Y, Liu X, Xuan Y and Hu S: Association between miR-27a genetic variants and susceptibility to colorectal cancer. Diagn Pathol 9: 146, 2014.
35. Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, Zhu YH and Zhang L: A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem 394: 415-420, 2013.
36. Oh J, Kim JW, Lee BE, Jang MJ, Chong SY, Park PW, Hwang SG, Oh D and Kim NK: Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep 31: 995-1002, 2014.
37. Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, Xu GH and Gao LB: A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol 35: 831-835, 2014.
38. Wang FJ, Ding Y, Mao YY, Jing FY, Zhang ZY, Jiang LF, Guo JF, Sun XJ, Jin MJ and Chen K: Associations between hsa-miR-603 polymorphism, lifestyle-related factors and colorectal cancer risk. Cancer Biomark 14: 225-231, 2014.
39. Ryan BM, McClary AC, Valeri N, Robinson D, Paone A, Bowman ED, Robles AI, Croce C and Harris CC: rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS One 7: e36306, 2012.
40. De Ruyck K, Duprez F, Ferdinande L, Mbah C, Rios-Velazquez E, Hoebers F, Praet M, Deron P, Bonte K, Speel EJ, et al: A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer. Cancer Epidemiol 38: 591-598, 2014.
41. Zhou B, Dong LP, Jing XY, Li JS, Yang SJ, Wang JP and Zhao LF: Association between miR-146aG>C and miR-196a2C>T poly-morphisms and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol 35: 7775-7780, 2014.
42. Palmieri A, Carinci F, Martinelli M, Pezzetti F, Girardi A, Cura F, Rubini C and Scapoli L: Role of the MIR146A polymorphism in the origin and progression of oral squamous cell carcinoma. Eur J Oral Sci 122: 198-201, 2014.
43. Wang N, Li Y, Zhu LJ, Zhou RM, Jin W, Guo XQ, Wang CM, Chen ZF and Liu W: A functional polymorphism rs11614913 in microRNA-196a2 is associated with an increased risk of colorectal cancer although not with tumor stage and grade. Biomed Rep 1: 737-742, 2013.
44. Tao T, Chen S, Xu B, Liu C, Wang Y, Huang Y and Chen M: Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls. Chin J Cancer Res 26: 315-322, 2014.
45. Li YJ, Zhang ZY, Mao YY, Jin MJ, Jing FY, Ye ZH and Chen K: A genetic variant in MiR-146a modifies digestive system cancer risk: a meta-analysis. Asian Pac J Cancer Prev 15: 145-150, 2014.
46. Wang J, Wang Q, Liu H, Shao N, Tan B, Zhang G, Wang K, Jia Y, Ma W, Wang N, et al: The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis 27: 779-788, 2012.
47. Dikeakos P, Theodoropoulos G, Rizos S, Tzanakis N, Zografos G and Gazouli M: Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population. Mol Biol Rep 41: 1075-1080, 2014.
48. Song MY, Su HJ, Zhang L, Ma JL, Li JY, Pan KF and You WC: Genetic polymorphisms of miR-146a and miR-27a, H. pylori infection, and risk of gastric lesions in a Chinese population. PLoS One 8: e61250, 2013.
49. Zeng Y, Sun QM, Liu NN, Dong GH, Chen J, Yang L and Wang B: Correlation between pre-miR-146a C/G polymorphism and gastric cancer risk in Chinese population. World J Gastroenterol 16: 3578-3583, 2010.
50. Zhou F, Zhu H, Luo D, Wang M, Dong X, Hong Y, Lu B, Zhou Y, Zhou J, Zhang Z, et al: A functional polymorphism in Pre-miR-146a is associated with susceptibility to gastric cancer in a Chinese population. DNA Cell Biol 31: 1290-1295, 2012.